263 related articles for article (PubMed ID: 34955849)
1. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
[No Abstract] [Full Text] [Related]
2. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
Zhuang HH; Qu Q; Long WM; Hu Q; Wu XL; Chen Y; Wan Q; Xu TT; Luo Y; Yuan HY; Lu Q; Qu J
Infection; 2024 Jun; ():. PubMed ID: 38884857
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection.
Xiao S; Fu Q; Miao Y; Zhao M; Lu S; Xu J; Zhao W
Front Microbiol; 2023; 14():1198926. PubMed ID: 37664109
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
Qu J; Xu J; Liu Y; Hu C; Zhong C; Lv X
Int J Antimicrob Agents; 2023 Aug; 62(2):106872. PubMed ID: 37247645
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant
Abu Jaber AMR; Basgut B; Hawan AA; Al Shehri AA; AlKahtani SA; Ahmed NJ; Abdi A
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534700
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant
Chen J; Liang Q; Chen X; Wu J; Wu Y; Teng G; Huang M
Infect Drug Resist; 2022; 15():655-667. PubMed ID: 35241917
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
Shi Y; Hu J; Liu P; Wang T; Wang H; Liu Y; Cao Q; Zuo X
Infect Dis Ther; 2021 Dec; 10(4):2721-2734. PubMed ID: 34652713
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
12. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem-resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.
Pu W; Fan L; Zhang Y; You D; Li M; Ma L
Pediatr Infect Dis J; 2023 Dec; 42(12):1124-1127. PubMed ID: 37725810
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant
Zhang F; Zhong J; Ding H; Liao G
Infect Drug Resist; 2021; 14():5165-5174. PubMed ID: 34908850
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
Kong W; Yang X; Shu Y; Li S; Song B; Yang K
Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
Gu J; Xu J; Zuo TT; Chen YB
J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of Ceftazidime/Avibactam for the Treatment of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Retrospective Study.
Lin J; Zhang L; Zhou M; Tian X; Chen J; Lu M; Liu Z
Infect Dis Ther; 2023 Aug; 12(8):2165-2177. PubMed ID: 37653121
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant
Zhang L; Ma Y; Zhao C; Zhao S; Zhao L; Yang Y; Wang Y; Meng H; Sun J
Infect Drug Resist; 2024; 17():239-248. PubMed ID: 38293316
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.
Chen J; Hu Q; Zhou P; Deng S
Infection; 2024 Feb; 52(1):19-28. PubMed ID: 37878197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
